Mesalamine in the Initial Therapy of Ulcerative Colitis.
Anti-Inflammatory Agents, Non-Steroidal
/ administration & dosage
Colitis, Ulcerative
/ drug therapy
Dibutyl Phthalate
Drug Compounding
Endoscopy, Gastrointestinal
Female
Humans
Maintenance Chemotherapy
Male
Mesalamine
/ administration & dosage
Pregnancy
Pregnancy Complications
Quality of Life
Remission Induction
Safety
Secondary Prevention
Chronic disorder
Crohn’s disease
Dibutyl phthalate
Endoscopic healing
Inflammatory bowel disease
Therapy
Ulcerative colitis
Journal
Gastroenterology clinics of North America
ISSN: 1558-1942
Titre abrégé: Gastroenterol Clin North Am
Pays: United States
ID NLM: 8706257
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
entrez:
30
10
2020
pubmed:
31
10
2020
medline:
24
7
2021
Statut:
ppublish
Résumé
Inflammatory bowel disease is a chronic disorder of intestinal inflammation and includes Crohn's disease and ulcerative colitis. The goal of therapy is to induce and maintain remission, which is achieved with conventional therapies. Mesalamine is considered a first-line therapy for ulcerative colitis. Clinical trials have confirmed its efficacy and safety in patients with mild to moderate ulcerative colitis. Doses of more than 2.4 g/d achieve significantly higher rates of clinical and endoscopic remission, with a decreased risk of relapse. Serious adverse effects are rare, but nonadherence is common. Mesalamine is considered safe in pregnancy, excluding formulations with dibutyl phthalate.
Identifiants
pubmed: 33121689
pii: S0889-8553(20)30070-4
doi: 10.1016/j.gtc.2020.07.002
pii:
doi:
Substances chimiques
Anti-Inflammatory Agents, Non-Steroidal
0
Dibutyl Phthalate
2286E5R2KE
Mesalamine
4Q81I59GXC
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
689-704Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Disclosure The authors have nothing to disclose.